Apolipoproteins and long-term prognosis in coronary heart disease patients.

[1]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[2]  U. Goldbourt,et al.  Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. , 2008, Journal of the American College of Cardiology.

[3]  A. Zwinderman,et al.  Role of the Apolipoprotein BApolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A CaseControl Analysis in EPIC-Norfolk , 2007, Annals of Internal Medicine.

[4]  V. Somers,et al.  Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. , 2006, The American journal of cardiology.

[5]  C. Packard,et al.  Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels , 2006, Journal of internal medicine.

[6]  J. Danesh,et al.  Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature‐based meta‐analysis of prospective studies , 2006, Journal of internal medicine.

[7]  G. Walldius,et al.  The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence , 2006, Journal of internal medicine.

[8]  G. Dagenais,et al.  Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. , 2006, The American journal of cardiology.

[9]  Nader Rifai,et al.  Non–High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men , 2005, Circulation.

[10]  Serkalem Demissie,et al.  Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[11]  S. Blankenberg,et al.  Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. , 2005, International journal of cardiology.

[12]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[13]  C. Meisinger,et al.  Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study , 2005 .

[14]  S. Haffner,et al.  Comparison of the Associations of Apolipoprotein B and Non–High-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in Patients With the Metabolic Syndrome in the Insulin Resistance Atherosclerosis Study , 2004, Circulation.

[15]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[16]  G. Dagenais,et al.  Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. , 2003, The American journal of cardiology.

[17]  E. Hawe,et al.  Nonfasting Apolipoprotein B and Triglyceride Levels as a Useful Predictor of Coronary Heart Disease Risk in Middle-Aged UK Men , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[18]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study☆ , 2002 .

[19]  A. Keech,et al.  Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels? , 2002, Circulation.

[20]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.

[21]  A. Sharrett,et al.  Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Circulation.

[22]  A. Zwinderman,et al.  Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[24]  D R Shapiro,et al.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, Circulation.

[25]  A. Moss,et al.  Thrombogenic factors and recurrent coronary events. , 1999, Circulation.

[26]  G. Dagenais,et al.  Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. , 1996, Circulation.

[27]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[28]  U. Goldbourt,et al.  Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). , 1993, The American journal of cardiology.